13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding

Parenteral Nutrition (PN) is the intravenous administration of essential nutrients—including dextrose, crystalline amino acids, intravenous lipid emulsions (IVLE), electrolytes, vitamins, and trace elements—directly into the systemic circulation, bypassing the gastrointestinal tract entirely. In the Nutritionist-Dietitian Licensure Examination (NDLE), clinical candidates must demonstrate absolute mastery of PN indications, vascular access osmolarity thresholds, macronutrient calculations, compounding stability, the life-threatening dynamics of Refeeding Syndrome, and long-term metabolic monitoring.

---

Indications and Clinical Criteria for Parenteral Nutrition

Parenteral nutrition is a complex, high-cost, and invasive medical therapy. It should be reserved exclusively for patients in whom the gastrointestinal tract is non-functional, perforated, or inaccessible:

Clinical Indications

1. Non-Functional Gastrointestinal Tract: Prolonged paralytic ileus ($>5\text{ to }7\text{ days}$), complete mechanical intestinal obstruction where surgical bypass is not feasible, or generalized diffuse peritonitis.
2. Severe Short Bowel Syndrome: Massive intestinal resection resulting in intestinal failure ($<100\text{ cm}$ remaining small bowel without colon, or $<60\text{ cm}$ with colon).
3. High-Output Enterocutaneous Fistula: Enterocutaneous fistula output exceeding $500\text{ mL/day}$, where feeding access distal to the fistula cannot be achieved.
4. Intractable Gastrointestinal Disorders: Severe intractable vomiting or diarrhea unresponsive to medical therapies, severe malabsorption syndromes, severe graft-versus-host disease (GVHD) of the gut, or severe mesenteric ischemia.
5. Failed Enteral Nutrition in Critical Illness: Critically ill patients who fail to tolerate post-pyloric enteral nutrition or whose enteral intake remains $<60\%$ of estimated requirements after 7 to 10 days of hospitalization.

Contraindications

• A functional, accessible gastrointestinal tract capable of absorbing adequate nutrients.
• Anticipated duration of therapy $<5\text{ days}$ in a previously well-nourished patient.
• Inability to obtain safe vascular access.
• Palliative settings where PN is contrary to advance directives or the patient's goals of care.
• Severe active hemodynamic instability, severe uncorrected electrolyte/acid-base derangements, or pulmonary edema (correct prior to initiating PN).

---

Peripheral Parenteral Nutrition (PPN) vs. Central Parenteral Nutrition (TPN)

The fundamental determinant distinguishing peripheral from central parenteral nutrition is the osmolarity of the solution, which dictates the required vascular diameter and blood flow velocity.

                               Vascular Access Determination
                                             │
                     ┌───────────────────────┴───────────────────────┐
                     ▼                                               ▼
      [Peripheral Access: PPN]                        [Central Access: TPN / CPN]
      - Cephalic / basilic veins                     - Superior Vena Cava (SVC)
      - Osmolarity CEILING: <= 900 mOsm/L            - Accommodates >900 to 2,000+ mOsm/L
      - Dextrose limit: <= 10% (D10W)                - Concentrated dextrose (20%–70% stock)
      - Large volume required (2.5–3.5 L/day)        - Fluid-restricted friendly (1–1.5 L/day)
      - Short-term support (<10–14 days)             - Long-term support (weeks, months, years)
      - Risk: Chemical thrombophlebitis              - Risk: Central line infections (CRBSI)

Comparison of PPN and Central TPN

Calculating Solution Osmolarity

To ensure a proposed peripheral PN admixture does not exceed the $900\text{ mOsm/L}$ safety ceiling, use standard osmolar coefficients:

$\text{Estimated Osmolarity (mOsm/L)} = [\text{g Dextrose/L} \times 5] + [\text{g Amino Acids/L} \times 10] + [\text{mEq Total Electrolytes/L} \times 2] + [\text{g Lipid/L} \times 0.7]$

Clinical Example: A 1-liter peripheral solution containing 100 g dextrose, 40 g amino acids, and 100 mEq total electrolytes: $\text{Osmolarity} = (100 \times 5) + (40 \times 10) + (100 \times 2) = 500 + 400 + 200 = 1{,}100\text{ mOsm/L}$ Because $1{,}100\text{ mOsm/L} > 900\text{ mOsm/L}$, this admixture cannot be infused peripherally and requires central venous access.

---

Parenteral Macronutrient Energetics and Compounding

                      Parenteral Macronutrient Substrates
                                       │
         ┌─────────────────────────────┼─────────────────────────────┐
         ▼                             ▼                             ▼
[Dextrose Monohydrate]      [Crystalline Amino Acids]      [Intravenous Lipid Emulsion]
- 3.4 kcal/gram              - 4.0 kcal/gram                - 10% IVLE = 1.1 kcal/mL
- Hydrated monosaccharide    - L-amino acid crystalline mix - 20% IVLE = 2.0 kcal/mL
- Min: 100–150 g/day         - Protein / 6.25 = Nitrogen    - 30% IVLE = 3.0 kcal/mL
- MAX GIR: 4–5 mg/kg/min     - NPC:N ratio calculations     - Soy vs. SMOF emulsion

1. Carbohydrates: Dextrose Monohydrate

• Energetic Density: In parenteral nutrition, dextrose is supplied as dextrose monohydrate (each D-glucose molecule crystallizes with one water molecule). Therefore, parenteral dextrose yields $3.4\text{ kcal/g}$, unlike anhydrous dietary carbohydrate which yields $4.0\text{ kcal/g}$.
• Minimum Requirement: At least $100\text{ to }150\text{ g/day}$ (approximately $2\text{ mg/kg/min}$) is mandatory to prevent ketosis, suppress hepatic gluconeogenesis, and spare somatic protein.
• Maximum Glucose Infusion Rate (GIR): $\text{GIR (mg/kg/min)} = \frac{\text{Total Daily Dextrose (g)} \times 1{,}000\text{ mg/g}}{\text{Patient Weight (kg)} \times 1{,}440\text{ min/day}}$ Or for a continuous hourly infusion: $\text{GIR (mg/kg/min)} = \frac{\text{Hourly Dextrose Infusion Rate (g/hr)} \times 1{,}000}{60\text{ min/hr} \times \text{Patient Weight (kg)}}$
• Physiological GIR Ceilings:
  • In critically ill, stressed adults: $4\text{ to }5\text{ mg/kg/min}$ (absolute recommended ceiling).
  • In stable, non-stressed long-term TPN patients: up to $7\text{ mg/kg/min}$.
• Consequences of Exceeding GIR: When dextrose infusion exceeds hepatic oxidative capacity (~$5\text{ to }7\text{ mg/kg/min}$), excess glucose is diverted into de novo lipogenesis in hepatocytes. This causes acute hepatic steatosis (fatty liver), marked hyperglycemia, hyperosmolar nonketotic coma, and hypercapnia. Lipogenesis from carbohydrate yields a Respiratory Quotient ($RQ$) of $1.2\text{ to }1.3$, generating an excessive carbon dioxide load ($\text{VCO}_2$) that precipitates respiratory acidosis and impedes weaning from mechanical ventilation.

2. Amino Acids: Crystalline L-Amino Acid Solutions

• Energetic Density: Supplied as balanced crystalline solutions containing essential and non-essential amino acids, yielding $4.0\text{ kcal/g}$.
• Nitrogen Conversions: $\text{Grams of Nitrogen (N)} = \frac{\text{Grams of Amino Acids (Protein)}}{6.25}$
• Non-Protein Calorie to Nitrogen Ratio (NPC:N): $\text{NPC:N} = \frac{\text{Total Dextrose Calories} + \text{Total Lipid Calories}}{\text{Total Grams of Nitrogen}}$
  • Normal, unstressed maintenance: $150:1\text{ to }200:1$
  • Moderate catabolic stress (surgery, infection): $100:1\text{ to }150:1$
  • Severe catabolic stress (major burns, severe trauma): $80:1\text{ to }100:1$

3. Lipids: Intravenous Lipid Emulsions (IVLE)

• Energetic Density: Intravenous lipid emulsions contain vegetable oils, glycerol (added for osmotic equilibrium), and egg yolk phospholipids (added as an emulsifier). Because glycerol contributes calories, the caloric density is volume-dependent:
  • 10% IVLE: $1.1\text{ kcal/mL}$ ($11\text{ kcal/g}$ of fat)
  • 20% IVLE: $2.0\text{ kcal/mL}$ ($10\text{ kcal/g}$ of fat)
  • 30% IVLE: $3.0\text{ kcal/mL}$ ($10\text{ kcal/g}$ of fat)
• Traditional Soybean Oil Emulsions (100% Soy): High in omega-6 polyunsaturated fatty acids (linoleic acid). Excessive omega-6 metabolism generates pro-inflammatory prostaglandins (PGE2) and leukotrienes (LTB4), which can suppress immune function and impair reticuloendothelial clearance.
• Modern SMOF Lipid Emulsions: Multi-oil composite emulsions formulated to optimize fatty acid profiles:
  • Soybean oil (30%): Supplies essential linoleic and $\alpha$-linolenic acids.
  • Medium-Chain Triglycerides (30%): Rapidly cleared from plasma and oxidized for energy; does not burden reticuloendothelial clearance.
  • Olive oil (25%): Rich in omega-9 monounsaturated oleic acid; neutral, resistant to lipid peroxidation.
  • Fish oil (15%): Rich in omega-3 fatty acids (EPA and DHA); exerts anti-inflammatory, pro-resolving, and immunoprotective effects.
• Essential Fatty Acid Deficiency (EFAD): Fat-free PN induces biochemical EFAD within 1 to 3 weeks. Manifestations include dry, scaly dermatitis, alopecia, thrombocytopenia, and impaired wound healing. Diagnosis is confirmed by a triene-to-tetraene (Holman) ratio $>0.2$. Prevented by providing $1\%\text{ to }2\%$ of total energy as linoleic acid and $0.5\%$ as $\alpha$-linolenic acid (or 250–500 mL of 20% IVLE once or twice weekly).
• Triglyceride Surveillance: Maintain serum triglycerides $<400\text{ mg/dL}$ (or $<250–300\text{ mg/dL}$ in acute pancreatitis). If serum triglycerides exceed $400\text{ mg/dL}$, hold or reduce IVLE to prevent lipid-induced pancreatitis.

4. Parenteral Micronutrient Adjustments

• Trace Elements in Liver and Kidney Dysfunction:
  • In cholestasis and biliary obstruction (elevated direct bilirubin, alkaline phosphatase), withhold copper and manganese. Both trace elements are excreted primarily via bile. Impaired excretion causes systemic accumulation, leading to copper hepatotoxicity and manganese neurotoxicity in the basal ganglia (Parkinsonian movement disorders).
  • In severe renal failure, withhold or monitor chromium and selenium, which are cleared by the kidneys.
• Iron Omission: Iron dextran or iron sucrose is generally omitted from daily PN admixtures because iron destabilizes lipid emulsions, promotes rapid bacterial proliferation, and increases the risk of anaphylactoid reactions. Iron is infused separately when indicated.

---

PN Compounding: 2-in-1 vs. 3-in-1 Admixtures and Precipitation Hazards

                             Parenteral Compounding Models
                                           │
                   ┌───────────────────────┴───────────────────────┐
                   ▼                                               ▼
           [2-in-1 Formulation]                           [3-in-1 / TNA / AIO]
  - Dextrose + Amino acids in bag                 - Dextrose + Amino acids + Lipids in 1 bag
  - Lipids infused separately (piggyback)         - Single infusion pump and line
  - Clear solution: easy visual inspection        - Milky white: OBSCURES precipitates!
  - Utilizes 0.22-micron sterilizing filter       - Requires 1.2-micron filter (0.22 clogs)
  - Higher chemical stability                     - Risk of lipid "cracking" & creaming

1. 2-in-1 Admixtures vs. 3-in-1 (Total Nutrient Admixtures - TNA)

• 2-in-1 Admixtures: Dextrose and amino acids are combined in a single primary infusion container, while lipids are infused separately via a secondary piggyback infusion line distal to the filter.
  • Advantages: Clear, translucent solution allows immediate visual inspection for particulate matter, hair, or chemical precipitates; higher chemical stability; permits in-line filtration with a 0.22-micron sterilizing filter (which retains bacteria and particulate matter).
  • Disadvantages: Requires two separate infusion lines/pumps, increasing nursing workload and the number of catheter violations.
• 3-in-1 Admixtures (Total Nutrient Admixture [TNA] / "All-in-One"): Dextrose, amino acids, and lipids are combined in a single container.
  • Advantages: Single container and single pump simplify administration, improve patient mobility, and reduce catheter manipulation.
  • Disadvantages: Milky-white, opaque emulsion completely obscures visual detection of particulate matter and precipitates; less stable; requires a 1.2-micron filter (a 0.22-micron filter would become clogged by lipid droplet particles); increased risk of emulsion destabilization.

2. Lipid Emulsion Destabilization: "Creaming" vs. "Cracking"

• Creaming: Lipid droplets rise to the surface of the admixture, forming a translucent, milky layer. It is reversible with gentle inversion.
• Cracking: Complete, irreversible destruction of the emulsion. Lipid droplets fuse together, forming a visible, free amber oil slick on the surface. Infusing a cracked emulsion is fatal, as large oil droplets ($>5\ \mu\text{m}$) cause acute pulmonary capillary microembolism. Factors that trigger cracking include acidic pH ($<5.0$) and high concentrations of trivalent ($Fe^{3+}$) or divalent ($Ca^{2+}, Mg^{2+}$) cations that neutralize the negative zeta-potential of phospholipid droplets.

3. Calcium-Phosphate Precipitation Hazards

Insoluble dibasic calcium phosphate ($CaHPO_4$) precipitate formation in PN solutions is a major physical-chemical hazard that can cause fatal microvascular pulmonary embolism. Compounding pharmacists and clinical dietitians must manage the factors governing solubility:

1. pH of the Admixture: The most critical determinant. Monobasic phosphate ($H_2PO_4^-$) is highly soluble, whereas dibasic phosphate ($HPO_4^{2-}$) is insoluble and rapidly precipitates with free calcium. Alkaline pH shifts equilibrium toward the insoluble dibasic form ($HPO_4^{2-}$). Acidic pH preserves the soluble monobasic form.
2. Choice of Calcium Salt: Calcium gluconate is always preferred over calcium chloride. Calcium chloride dissociates rapidly and completely, yielding high concentrations of free reactive $Ca^{2+}$. Calcium gluconate has a lower dissociation constant, releasing ionic calcium slowly and minimizing precipitation risk.
3. Amino Acid Concentration: Amino acids act as chemical buffers and weak chelators; high amino acid concentrations ($>2.5\%$) bind calcium and keep it in solution, inhibiting precipitation.
4. Ambient Temperature: Precipitation is an endothermic reaction. Warming a PN bag to room or body temperature promotes precipitation. A clear refrigerated solution may precipitate once hung at room temperature.
5. Compounding Sequence: Always add phosphate early to the dextrose/amino acid base, agitate thoroughly, and add calcium gluconate near the end of compounding.